University Of Milan
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
The University of Milan’s Department of Infectious Diseases is conducting studies focused on hospital‑acquired bacterial pneumonia caused by Acinetobacter baumannii complex. These trials aim to assess safety and effectiveness of new antimicrobial agents, improving treatment options for patients on ventilators.
- Safety and tolerability of single‑day dose‑escalating OMN6
- Pharmacokinetic profiling in pneumonia patients
- Impact on disease progression and recovery
The site combines academic expertise with commercial collaboration, leveraging its Milan location to advance respiratory infection therapies.
Virus Diseases
Research at the University of Milan also targets COVID‑19 caused by SARS‑CoV‑2, evaluating therapeutic interventions to reduce disease progression and mortality in hospitalized patients.
- Baricitinib added to standard of care in severe cases
- Adaptive platform trial assessing multiple antiviral strategies
- Outcomes for moderate disease progression prevention
These investigations are part of a European adaptive pandemic platform, reflecting the institution’s commitment to rapid, evidence‑based solutions for viral infections.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Omnix Medical Ltd.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Of Milan
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of OMN6 in Patients with Acinetobacter baumannii Complex-Induced HABP or VABP | Omnix Medical Ltd. | Phase II | Recruiting | Jul 2026 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Baricitinib | 1 | Unknown | 2021-06-03 | 2021-06-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.